[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6091 followers
Created: 2025-07-23 09:35:50 UTC

Syngene’s Q1 FY2026: Revenue Growth & Strategic Expansions in US & India 📊🌍 | MCap XXXXXXXXX Cr

- Revenue Growth: Standalone revenue rose to ₹7,993M in Q1 FY2026 (vs. ₹7,265M in Q1 FY2025); consolidated revenue reached ₹8,745M (vs. ₹7,897M).
- Profit Metrics: Standalone PBT at ₹842M (down from ₹988M YoY); consolidated PBT flat at ₹1,013M. EPS held steady (standalone: ₹1.84; consolidated up to ₹2.16 from ₹1.89).
- Dividend Proposal: Board recommends final dividend of ₹1.25 per equity share (subject to approval).
- US Expansion: Syngene USA acquired a biologics site, adding 50,000L bioreactor capacity (₹2,981M capitalized as CWIP).
- Bangalore Facility: ₹3,438M invested in biologics manufacturing, leading to ₹36M higher depreciation in Q1.

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of X pages)

![](https://pbs.twimg.com/media/GwiFgEObcAAd5-2.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947953792466518077/c:line.svg)

**Related Topics**
[eps](/topic/eps)
[mcap](/topic/mcap)
[india](/topic/india)
[quarterly earnings](/topic/quarterly-earnings)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1947953792466518077)